Skip to main content

Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes.

Publication ,  Journal Article
Il'yasova, D; Morrow, JD; Wagenknecht, LE
Published in: Obes Res
September 2005

OBJECTIVE: Free radicals have been implicated in the etiology of type 2 diabetes. Cross-sectional studies have demonstrated associations between oxidative damage and type 2 diabetes. However, no prospective data on this association are available. RESEARCH METHODS AND PROCEDURES: A case control study was conducted within the prospective cohort of the Insulin Resistance Atherosclerosis Study: 26 cases who developed type 2 diabetes in the follow-up period and 26 controls who remained free of type 2 diabetes were randomly selected. Oxidative status was assessed by measuring 2,3-dinor-5,6-dihydro-15-F2t-isoprostane (F2-IsoPM) in baseline urine samples using gas chromatography/mass spectroscopy. Type 2 diabetes was defined by serial oral glucose tolerance tests and World Health Organization criteria. RESULTS: Urinary F2-IsoPM varied between 0.18 and 2.60 ng/mg creatinine; 25th/50th/75th percentiles were 0.42, 0.60, and 0.89, respectively. A trend toward higher levels were observed in women and in persons with impaired glucose tolerance at baseline (p = 0.1). F2-IsoPM increased with BMI (r = 0.36, p = 0.01). After adjustment for age, gender, baseline impaired glucose tolerance status, and BMI, F2-IsoPM levels were inversely associated with development of type 2 diabetes: odds ratio = 0.32 (95% confidence interval, 0.12 to 0.81) for the difference between the 75th and 25th percentiles. DISCUSSION: These results suggest that oxidative damage is not a cause of type 2 diabetes. Positive cross-sectional associations of F2-IsoPM with the risk factors for diabetes, BMI, and impaired glucose tolerance and inverse associations with development of type 2 diabetes indicate that F2-IsoPM might reflect a compensatory mechanism.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Obes Res

DOI

ISSN

1071-7323

Publication Date

September 2005

Volume

13

Issue

9

Start / End Page

1638 / 1644

Location

United States

Related Subject Headings

  • Statistics, Nonparametric
  • Risk Factors
  • Regression Analysis
  • Pilot Projects
  • Oxidative Stress
  • Middle Aged
  • Male
  • Lipid Peroxidation
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Il’yasova, D., Morrow, J. D., & Wagenknecht, L. E. (2005). Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res, 13(9), 1638–1644. https://doi.org/10.1038/oby.2005.201
Il’yasova, Dora, Jason D. Morrow, and Lynne E. Wagenknecht. “Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes.Obes Res 13, no. 9 (September 2005): 1638–44. https://doi.org/10.1038/oby.2005.201.
Il’yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res. 2005 Sep;13(9):1638–44.
Il’yasova, Dora, et al. “Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes.Obes Res, vol. 13, no. 9, Sept. 2005, pp. 1638–44. Pubmed, doi:10.1038/oby.2005.201.
Il’yasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. Obes Res. 2005 Sep;13(9):1638–1644.

Published In

Obes Res

DOI

ISSN

1071-7323

Publication Date

September 2005

Volume

13

Issue

9

Start / End Page

1638 / 1644

Location

United States

Related Subject Headings

  • Statistics, Nonparametric
  • Risk Factors
  • Regression Analysis
  • Pilot Projects
  • Oxidative Stress
  • Middle Aged
  • Male
  • Lipid Peroxidation
  • Humans
  • Female